At the time of writing, Vertex Pharmaceuticals, Inc. [VRTX] stock is trading at $487.37, down -0.14%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRTX shares have gain 4.23% over the last week, with a monthly amount drifted -1.72%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] stock has seen the most recent analyst activity on August 05, 2024, when Barclays downgraded its rating to a Equal Weight and also boosted its price target to $509 from $472. Previously, Redburn Atlantic started tracking the stock with Buy rating on June 27, 2024, and set its price target to $545. On April 11, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $438 on the stock. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $515 on February 15, 2024. Evercore ISI downgraded its rating to a In-line and raised its price target to $438 on February 06, 2024. Bernstein downgraded its rating to Mkt Perform for this stock on February 02, 2024. In a note dated January 31, 2024, Robert W. Baird downgraded an Underperform rating on this stock but restated the target price of $325.
For the past year, the stock price of Vertex Pharmaceuticals, Inc. fluctuated between $340.83 and $510.64. Currently, Wall Street analysts expect the stock to reach $381.05 within the next 12 months. Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] shares were valued at $487.37 at the most recent close of the market. An investor can expect a potential drop of -21.82% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
According to Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX], the company’s sales were 10.32B for trailing twelve months, which represents an 6.02% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.04%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is -0.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 483.56 points at the first support level, and at 479.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 491.15, and for the 2nd resistance point, it is at 494.94.
Ratios To Look Out For
It is important to note that Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX] has a current ratio of 2.52. On the other hand, the Quick Ratio is 2.26, and the Cash Ratio is 1.29. Considering the valuation of this stock, the price to sales ratio is 12.19, the price to book ratio is 8.51.
Transactions by insiders
Recent insider trading involved Bhatia Sangeeta N., Director, that happened on Aug 08 ’24 when 1292.0 shares were sold. EVP and CMO, Bozic Carmen completed a deal on Aug 07 ’24 to sell 2280.0 shares. Meanwhile, Director Bhatia Sangeeta N. bought 1292.0 shares on Aug 08 ’24.
